Moderna could have to wait until as late as December to analyse data from its Covid-19 vaccine trial, longer than would be necessary to meet the Trump administration’s hopes of issuing an emergency approval ahead of the US election.
The Boston-based biotech company said on Thursday it had enrolled more than 25,000 participants in its trial, with more than 10,000 of those having already received both doses in the vaccine course.
It also set out a slower analysis timeline than rival Pfizer and its partner BioNTech, which said they would have their key data by the end of October. Shares in Moderna fell 2.4 per cent to $67.22 on the news.
您已阅读21%（641字），剩余79%（2410字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。